September 19th 2024
Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
May 25th 2022
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
May 18th 2022
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
May 11th 2022
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
April 13th 2022
A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
August 30th 2021
Treatment Advances in mCSPC
A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.
August 23rd 2021
A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.